Skip to main content
Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia.
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group.
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD.
Challenging T-ALL to IL-7Rp dual inhibition.
Higher Abatacept Exposure Decreases Acute GVHD Risk Without Increasing Adverse Events.
NFIA-ETO2, TP53, and erythroid leukemogenesis.
How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults.
Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups.